Skip to main content

Table 1 Patient characteristics and survival analysis (by clinicopathological subtype)

From: Contrast enhanced computed tomography is indicative for angiogenesis pattern and display prognostic significance in breast cancer

Characteristic

Luminal A (n = 119)

Luminal B Ki67+ (n = 52)

Luminal B HER2 + (22)

HER2 overexpression (16)

TNBC (46)

Statistics

P

Age (years)

51.67 ± 10.10

50.88 ± 8.16

55.41 ± 8.98

52.13 ± 6.49

51.91 ± 10.90

0.896

0.467

Menopause

     

2.378

0.667

Postmenopausal

56

24

14

7

22

  

Premenopausal

63

28

8

9

24

  

Family history

     

2.075

0.722

No

109

49

21

16

42

  

Yes

10

3

1

0

4

  

Diameter

2.15 ± 0.98

2.32 ± 0.94

2.43 ± 1.07

3.09 ± 1.49

2.50 ± 1.18

3.292

0.012

Quadrant

     

16.851

0.395

Areolar

3

1

0

0

1

  

Inner upper

28

8

0

2

7

  

Inner lower

14

5

1

2

3

  

Outer lower

21

11

3

2

6

  

Outer upper

53

27

18

10

29

  

Enhancement patterns

     

59.901

0.000

Homogeneous

40(33.6%)

18(34.6%)

7(31.8%)

5(31.3%)

12(26.1%)

  

Heterogeneous

71(59.7%)

29(55.8%)

8(36.4%)

3(18.8%)

10(21.7%)

  

Peripherals

8(6.7%)

5(9.6%)

7(31.8%)

8(50.0%)

24(52.2%)

  

Difference of MVD (Edge - Center)

3.12 ± 6.26

3.18 ± 7.95

7.61 ± 8.53

7.98 ± 8.97

10.23 ± 8.72

9.543

0.000

Grade of DMVD

     

42.300

0.000

Uniform distribution

102(85.7%)

44(84.6%)

14(63.6%)

6(37.5%)

21(45.7%)

  

Uneven distribution

17(14.3%)

8(15.4%)

8(36.4%)

10(62.5%)

25(54.3%)

  

Histological grade

     

30.927

0.000

I

37(31.1%)

16(30.8%)

0(0%)

1(6.3%)

9(19.6%)

  

II

77(64.7%)

29(55.8%)

16(72.7%)

10(62.5%)

34(73.9%)

  

III

5(4.2%)

7(13.5%)

6(27.3%)

5(31.3%)

3(6.5%)

  

Cancer thrombosis

     

7.806

0.099

Negative

89

41

11

10

34

  

Positive

30

11

11

6

12

  

Nodal metastasis

     

6.825

0.145

Negative

60

24

8

3

23

  

Positive

59

28

14

13

23

  

Number of metastatic nodes

2.09 ± 4.16

2.94 ± 5.01

6.77 ± 9.63

11.88 ± 11.37

4.89 ± 9.70

9.167

0.000

Clinical stage

     

50.721

0.000

I

33(27.7%)

15(28.8%)

1(4.5%)

0(0%)

10(21.7%)

  

IIA

38(31.9%)

11(21.2%)

10(45.5%)

4(25.0%)

13(28.3%)

  

IIB

39(32.8%)

21(40.4%)

4(18.2%)

4(25.0%)

16(34.8%)

  

IIIA

7(5.9%)

3(5.8%)

3(13.6%)

3(18.8%)

2(4.3%)

  

IIIB

1(0.8%)

2(3.8%)

2(9.1%)

1(6.3%)

1(2.2%)

  

IIIC

1(0.8%)

0(0%)

2(9.1%)

4(25%)

4(8.7%)

  

IV

0(0%)

0(0%)

0(0%)

0(0%)

0(0%)

  

P53 (%)

27.76 ± 30.19

32.65 ± 34.17

41.55 ± 30.32

30.19 ± 32.23

35.50 ± 35.33

1.141

0.338

Operation

     

5.455

0.244

Mastectomy

102

47

21

16

43

  

Tumorectomy

17

5

1

0

3

  

Chemotherapy program

     

49.253

0.002

Not performed

1(0.8%)

0(0%)

0(0%)

0(0%)

1(2.2%)

  

CMF

2(1.7%)

0(0%)

0(0%)

0(0%)

0(0%)

  

CAF or AC

42(35.3%)

17(32.7%)

2(9.1%)

0(0%)

11(23.9%)

  

CEF or EC

21(17.6%)

12(23.1%)

10(45.5%)

5(31.3%)

14(30.4%)

  

T or TC or TP

42(35.3%)

15(28.8%)

4(18.2%)

2(12.5%)

13(28.3%)

  

TAC or A-T

10(8.4%)

8(15.4%)

6(27.3%)

9(56.3%)

7(15.2%)

  

Radiotherapy

     

6.682

0.154

Not performed

67

27

10

4

27

  

Performed

52

25

12

12

19

  

Endocrine therapy

     

262.436

0.000

Not performed

0(0%)

0(0%)

0(0%)

16(100%)

46(100%)

  

TAM

75(63.0%)

32(61.5%)

12(54.5%)

0(0%)

0(0%)

  

LHRH

11(9.2%)

7(13.5%)

0(0%)

0(0%)

0(0%)

  

AI

33(27.7%)

13(25.0%)

10(45.5%)

0(0%)

0(0%)

  

Targeted therapy

     

33.619

0.000

Not performed

119(100%)

52(100%)

20(90.9%)

13(81.3%)

46(100%)

  

Performed

0(0%)

0(0%)

2(9.1%)

3(18.8%)

0(0%)

  

Overall survival

99.2%

98.1%

86.4%

87.5%

91.3%

17.629

0.024

Event

1

1

3

2

4

  

Deaths

1

1

3

2

3

  

Lost to follow-up

0

0

0

0

1

  

Median survival time

54.0

48.0

36.0

29.4

35.2

31.845

0.000

Disease-free survival

98.3%

94.3%

72.7%

75.0%

82.6%

56.588

0.001

Event

2

3

6

4

7

  

Local recurrence

0

1

0

0

0

  

Contralateral breast cancer

1

1

2

0

0

  

Lung metastasis

0

0

0

1

1

  

Hepatic metastasis

0

0

2

1

2

  

Brain metastasis

0

0

0

1

2

  

Multi-organ

1

1

2

1

2

  

Lost to Follow-up

0

0

0

0

1

  

Disease-free survival

54.0

48.0

35.4

22.5

31.7

59.248

0.000

Follow-up time

     

4.741

0.001

Median

23.0

25.5

30.5

17.0

20.0

  

Range

12-59

12-49

12-38

12-25

12-53

  
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us